Scientific Programme

Endorsed by
ACCADEMIA
LIMPE-DISMOV
DECEMBER 3, 2016 FIRENZE
ACCADEMIA ITALIANA
MALATTIA DI PARKINSON
E DISORDINI DEL MOVIMENTO
IPAD 4
CONFERENCE REGISTRATION
Registration fee for non members: € 375,00 + VAT 22%
Registration fee for Accademia Limpe, Sin and EAN members: special rate at € 187,50 + VAT 22%
Registration fee includes: conference kit, admission to all the scientific sessions, lunch and coffee breaks. It is possible to register
online on the Official Site: http://www.ipadcongress.com
CONFERENCE VENUE
HOTEL LONDRA
Via J. Da Diacceto 18
50123 Firenze
www.concertohotels.com
OFFICIAL LANGUAGE
English is the official language of the Conference. No simultaneous translation will be provided.
CONTINUING MEDICAL EDUCATIONS ( CME )
Italian CME credits: 5,3
Organizing Secretariat
First Class S.r.l. Meetings and Conferences - Viale Italia, 173 - 57127 Livorno - Via G. Carducci 11, 20123 Milano - Italy
Ph: +39 0586 84 98 11 - Email: [email protected]
Supported by unrestricted educational grants by
TH
WEBSITE http://www.ipadcongress.com
4 INTERNATIONAL CONFERENCE ON
NEW THERAPIES FOR PARKINSON AND
ALZHEIMER DISEASES
SCIENTIFIC BOARD AND FACULTY
CONFERENCE ORGANIZERS
Ubaldo Bonuccelli - Pisa
Filippo Baldacci - Pisa / Paris
Sandro Sorbi - Florence
Saturday December 3
08:45
Opening: S. Sorbi, U. Bonuccelli
09:00 - 11:00
Epidemiology, Genetics and Biomarkers: What's new
Chairmen: A. Federico - L. Bracco
Paolo Barone - Salerno
Ubaldo Bonuccelli - Pisa
Laura Bracco - Firenze
Roberto Ceravolo - Pisa
Ruggero Fariello - Lugano
Antonio Federico - Siena
Daniela Galimberti - Milano
Roberto Marconi - Grosseto
Massimo Musicco - Milano
Benedetta Nacmias - Firenze
The 4th International Conference on New Therapies for Parkinson and
Dementias –IPAD4 will take place in Florence on December 3, 2016.
The conference will bring together experts of neurodegenerative
diseases coming from the academic world, hospital centres and
pharmaceutical industry. The meeting will focus on the new possibilities of preclinical and early diagnosis, and on the more innovative
pharmacological and non-pharmacological therapies.
The results of clinical trials will be evaluated and discussed, as well as
ongoing studies and the expected outcomes, drugs' pipeline, nonpharmacological therapies, perspectives on biomarkers and on future
diagnostic-therapeutic scenario and unmet needs of patients with
parkinsonian syndromes and dementias.
Alessandro Padovani - Brescia
Anna Poggesi - Firenze
Andrew Siderowf - Indianapolis
Sandro Sorbi - Firenze
Federica Vannetti - Firenze
Vissia Viglietta - Boston
Coffee break
11:30 - 13:00
Lunch
14:00 - 16:00
New Therapeutic horizons 1
Chairmen: U. Bonuccelli - B. Nacmias
I-MAO B inhibitors in PD - P. Barone
Games for Dementia - F. Vannetti
Amyloid antibodies in AD-focus on aducanumab - V. Viglietta
Vascular dementia - A. Poggesi
LOCAL ORGANIZING COMMITTEE
Filippo Baldacci - Pisa
Laura Bracco - Firenze
Daniela Frosini - Pisa
Filippo Giorgi - Pisa
Benedetta Nacmias - Firenze
Alberto Pupi - Firenze
Gloria Tognoni - Pisa
Early diagnosis and Imaging Biomarkers
Chairmen: M. Musicco - A.Padovani
Prodromal PD - R. Ceravolo
AD Imaging - A.Pupi
Molecular Imaging of Neurodegenerative Disorders - A. Siderowf
Sandro Sorbi - Ubaldo Bonuccelli
Congress Presidents
Giulio Perugi - Pisa
Alberto Pupi - Firenze
Epidemiology of Neurodegeneration - M. Musicco
PD genetics - A. Federico
AD genetics - B. Nacmias
AD/PD biomarkers - F. Baldacci
Coffee break
16:30 - 18:00
New Therapeutic horizons 2
Chairmen: S. Sorbi - R. Marconi
Antiamyloid and antiTAU drugs in AD - D. Galimberti
Antisynuclein agents in PD - R. Fariello
Psychiatric comorbidities - G. Perugi